Journal of Hepatology

Papers
(The H4-Index of Journal of Hepatology is 107. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
THU-192 Liver steatosis assessed by controlled attenuation parameter in patients with primary biliary cholangitis2579
SAT-521 Impact of centre type on treatment and survival outcomes in hepatocellular carcinoma (HCC)2056
FRI-247 Association of plasma magnesium with MASH and cirrhosis: combined data from multiple therapeutic trials including more than 10, 000 patients2014
THU-457 Outcome of liver transplantation in patients with hepatocellular carcinoma previously treated with immune checkpoint inhibitorbased therapy-first results from an international multicenter regi1791
OS-077 Added value of a combination of positron emission tomography with 18F-FDG and 18 F-Fluorocholine for staging optimization and treatment modification in patients with hepatocellular carcinoma: t788
FRI-195 Genetically determined circulating protein biomarkers and risk of advanced fibrosis687
WED-257 FibroScan compared to liver biopsy for accurately detecting recurrent hepatic steatosis and fibrosis after liver transplantation for metabolic dysfunction-associated steatohepatitis672
WED-092 Hyperuricemia leads to early cognitive dysfunction and neuronal cell injury in bile-duct ligated rats517
THU-447 Incidence and predictors of complications following percutaneous liver biopsy: a multicenter study407
TOP-311-YI Subtypes of steatotic liver disease have differing clinical outcomes396
WED-495 The impact of integration and decentralization of HBV services on enhancing the HBV care continuum: an interrupted time series359
OS-004 Testing for hepatitis C virus infection in prisons in England: room for improvement358
FRI-475-YI NADPH oxidase 1 inhibition as therapeutic strategy in hepatocellular carcinoma: insights from human-relevant models352
WED-058-YI High shear stress induced PIEZO1 activation promotes cytoskeleton remodelling and a nuclear deformation develops pro-thrombotic microenvironment and contributes to portal hypertension339
OS-111 Predictive genomic biomarkers for Atezolizumab plus Bevacizumab combination immunotherapy response in liver cancer: insights from the IMbrave150 trial335
SAT-479-YI Lower frequency of PNPLA3 in african populations and divergent associations with hepatocellular carcinoma325
THU-099-YI Small duct primary sclerosing cholangitis is not associated with a heightened risk of colorectal cancer compared to inflammatory bowel disease alone310
THU-219 Inhibition of HSD17B13 by INI-822 phenocopies the hepatic lipidomic profile of humans with the protective allele300
SAT-070 Argon plasma coagulation or endoscopic band ligation for gastric antral vascular ectasia: a randomized comparative analysis296
THU-114 Alkaline phosphatase levels at 6 months as a predictor of response to ursodeoxycholic acid at 1 year in patients with primary biliary cholangitis295
FRI-457 CXCL12 restricts hepatocellular carcinoma progression by shaping the tumor microenvironment in liver fibrosis294
THU-040-YI Establishment of the irish hepatology nurses association: an association for nurses working in liver disease in Ireland288
SAT-009 Increased prevalence of metabolic-alcohol liver disease in Europe and of metabolic dysfunction-associated steatotic liver disease in the Americas. Results of the global IMPROVEMENT study280
WED-524-YI Multi-omics study of chronic liver diseases with rifaximin treatment279
FRI-067 Impact of Farnesoid X receptor polymorphisms on prognosis in hepatocellular carcinoma277
SAT-418 Prevalence of hepatitis C virus infection in a nursing home: a frequently overlooked submerged population263
SAT-194 Effect of statin therapy in patients with obesity and cirrhosis secondary to metabolic dysfunction-associated steatotic liver disease (MASLD) on pre-liver transplant mortality229
FRI-245 Longitudinal follow-up of Fib-4 in patients at risk of steatotic liver disease (SLD) receiving low-dose Methotrexate treatment (LDMTX): results from the CIRT randomized placebo-controlled Tria229
THU-093 Biochemical response and liver stiffness variation over time predict liver-related events in patients with primary biliary cholangitis treated with Obeticholic acid226
WED-483 Performance comparison of four hepatitis E antibodies detection methods215
FRI-470 Deciphering the role of FXR in the rewiring of Treg polarization in hepatocellular carcinoma211
SAT-041 Real-world evidence of magnesium isoglycyrrhizinate for perioperative protection against hepatic injury in patients undergoing hepatectomy204
THU-405 Analysis of a decentralized model interdisciplinary for the elimination of HCV in vulnerable population in the province of Huelva (Spain). To continue advancing in the elimination of hepatitis202
THU-087 Herpesvirus viremia-cause or consequence of ACLF? Higher prevalence of cytomegalovirus, Epstein-Barr virus and herpes simplex virus viremia in patients with acute-on-chronic liver failure201
WED-439 Linkage of anti‐HCV reactive persons to HCV care and treatment services in Georgia199
WED-548 Rifaximin-alpha acts through increased abundance of Lactobacillus spp. in murine models of chronic liver disease198
FRI-258 No evidence for viral escape mutations in immunodominant HCV-specific CD4 T cell epitopes196
FRI-260 Identification of hepatitis B virus epitopes presented by human leukocyte antigen A*11:01 as potential targets for immunotherapy195
THU-270 HBV genotype association with response to xalnesiran in nucleos (t)ide analogue treated participants with chronic hepatitis B infection in the Piranga phase 2 platform study194
OS-020 Reviewing the utility of genetic cholestasis testing in adults with cholestatic liver disease194
OS-044 Liver sinusoidal endothelial cell BRD4 drives inflammatory angiocrine signaling in liver fibrosis192
FRI-144 Abrogation of hepatic TRb action protects the liver from acute liver injury187
THU-489 Disruption of receptor-interacting protein kinase 1 post-translational modifications in alcohol-associated liver disease186
LBP-015 Comparison of endoscopic ultrasound portosystemic gradient with HVPG and direct porto-systemic pressure gradient measurements185
FRI-166 Real-world evidence on clinical outcomes and microbiome changes after healthy donor stool transplantation as palliative therapy compared to best supportive care in patients with unstable decom184
FRI-161 Single-cell RNA sequencing reveals a fundamental role of LCN2+ neutrophils in the innate immune response in drug-induced acute-on-chronic liver failure180
OS-075 Dual plasma molecular adsorption system therapy in patients with acute-on-chronic liver failure: a non-randomized clustercontrolled study (PADSTONE)180
WED-086 Clinical evaluation of multimarker algorithmic scores for detection of early stage hepatocellular carcinoma in high-risk liver patients175
WED-153 A patient charter for hepatocellular carcinoma: a co-created community call for action on equitable access to early diagnosis and multidisciplinary care175
SAT-113 The intratumoral microbiome in HCC and its impact on treatment response172
WED-083 Role of Child-Turcotte-Pugh and ALBI scores in patients with non-cirrhotic hepatocellular carcinoma172
WED-262 Prolonged cholestasis following hepatitis A : what lies beneath171
FRI-247 In vitro characterization of elebsiran (VIR-2218), an investigational siRNA therapeutic targeting hepatitis B virus168
SAT-367 UNITED study: results of the up-titration phase of an open label, multicenter, prospective study to characterize the pharmacokinetics and pharmacodynamics of trientine dihydrochloride and to i168
SAT-162 Epidemiology and Risk factors for development of AKI-HRS based on the new consensus definition166
THU-069 A composite score of PRO-C6 and platelet count is prognostic for liver-related outcomes in patients with chronic hepatitis C164
FRI-044 Dynamic adaptations of CD8+γδ T cells in acute and chronic hepatitis E virus infection162
TOP-072-YI Human cirrhotic ascites contains myeloid reprogrammed T-cells capable of enhancing peritoneal immune surveillance159
WED-164 Cirrhotic patients with acute variceal bleeding and an indication for preemptive-TIPS: real-life results158
FRI-036 Single nucleotide polymorphisms of the vitamin D receptor and their impact on vitamin D- and Interleukin-6 levels in liver cirrhosis and acute-on-chronic-liver failure155
SAT-178 Quantitative measurements of prothrombin in patients with cirrhosis and ascites: a validation study150
SAT-205 Dynopenia predicts mortality in patients with liver cirrhosis and hepatocellular carcinoma150
TOP-508 Derivation and validation of a new donor risk score incorporating graft steatosis and donor diabetes mellitus150
THU-133-YI Risk of hypoglycemia in people with cirrhosis without diabetes149
FRI-062 Trained human bone marrow mesenchymal stem cells enhance immunoregulatory responses and alleviate ConA-induced acute liver failure148
FRI-481 Feasibility and effectiveness of liver transplantation following immunotherapy in patients with hepatocellular carcinoma145
THU-334 Cholestasis as a predictor of PSC in inflammatory bowel disease: insights from a romanian cohort study144
FRI-328 CCL24 blockade alters the proteomic profile of patients with primary sclerosing cholangitis and down-regulates central disease processes143
WED-121 Comparison of clinical characteristics, risk factors and prognosis of HCC patients with lean and non-lean MASLD undergoing surgical resection143
THU-308-YI Long-term evaluation of controlled attenuation parameter for steatosis monitoring in autoimmune hepatitis143
THU-178 Siglec-5 is a functional biomarker that contributes to poor prognosis in patients with liver cirrhosis141
SAT-136-YI Identification of prognosis determining risk factors in outpatients with cirrhosis141
WED-145 Morphomolecular proliferative disease and microvascular invasion characterize PET-CT positive hepatocellular carcinoma cases: a single-center pilot study140
WED-367-YI Frequency and risk factors of fibrosis staging discrepancies between transient elastography and liver biopsy in patients with metabolic-associated steatotic liver disease: role of obesity a138
WED-373 Agreement between hepatic histology and non-invasive methods and their ability to detect MASLD/MASH among morbidly obese patients undergoing bariatric surgery: an egyptian crosssectional study137
SAT-436 Efficacy of Imeglimin in MASLD with type 2 diabetes: a multicenter study135
SAT-417-YI Sex disparities in response to low-carb, high-fat diet in MASLD135
FRI-407 Adding the serotonergic agonist psilocybin to semaglutide as a novel combination therapy to cure MASLD135
WED-405 PRO-C4, a biomarker of perisinusoidal fibrosis, is related to cardiometabolic risk factors, steatosis, and liver stiffness134
WED-490 Ultrasound-derived visceral adipose tissue: an easily obtainable adiposity index strongly associated with metabolic dysfunctionassociated steatotic liver disease and metabolic parameters133
FRI-335 Therapeutic potential of a GHRH analog in experimental MASLD132
FRI-010 Economic evaluation of biomarker-base surveillance for hepatocellular carcinoma in thai patients with compensated liver cirrhosis129
TOP-016 Genetic determinants of hepatitis B surface antibody disappearance in Taiwan’s vaccinated generations: a genome- wide association study125
THU-405 Impact of ultra processed foods on metabolic dysfunctionassociated steatotic liver disease: limitations of the NOVA classification124
TOP-505 Evaluation of a non-invasive pathway for advanced fibrosis detection and liver-related outcomes prognosis in the general population from China, United Kingdom, and United States123
FRI-024 Living with liver disease: patient and carer experiences in the United Kingdom122
WED-279 No DDI between Bemnifosbuvir/Ruzasvir and Bictegravir/ Emtricitabine/Tenofovir Alafenamide120
Submit your late-breaker abstract for the EASL Congress 2024 between 27 March - 10 April119
The space of Mall confirmed in humans: A response to “Portal venous branches as an anatomic railroad for a gut-bile duct axis”118
Dual effects of brown-fat activation limit hepatocellular carcinoma (HCC) progress in steatotic liver117
The effects of a structured dietetics intervention in patients with non-alcoholic fatty liver disease116
Automation of hepatitis C screening through electronic health record algorithm115
The LIVERSCREEN project’s goal is to to establish a population-based screening programme for liver fibrosis utilising non-invasive markers115
Portal venous branches as an anatomic railroad for a gut-bile duct-axis115
Reply to: “A comment on `A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B’”115
Altered gut barrier integrity as a mediator of host-microbiome interactions in diabetic patients with advanced Non-alcoholic fatty liver disease114
LBP-036 Final results from the phase 3 REGENERATE trial evaluating the effects of obeticholic acid in patients with pre-cirrhotic fibrosis due to metabolic dysfunction-associated steatohepatitis114
Feasibility of a home-based, virtually-delivered, group exercise intervention in older patients with liver cancer (TELEX-Liver Cancer)114
LBP-016 Carvedilol versus propranolol in the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis114
Prevalence and predictors of HDV viremia in anti-HDV positive patients of the HEllenic multicenter ReAl-life CLInical Study (HERACLIS-HDV)112
Viral like particle analysis shows changes with PPIs and may be more sensitive than metagenomics to study PPI modulation of virome in cirrhosis111
Platelet, elastography, age, sex and etiology for hepatocellular carcinoma surveillance in patients with advanced chronic liver disease: Please algorithm111
Hepatitis C seroconversion rates among individuals with repeated testing-Georgia, 2017–2021111
Micro-elimination of chronic hepatitis C virus in patients with psychiatric disorders: a multidisciplinary strategy in the outpatient mental health center109
HBV infection reshapes host chromatin accessibility and affects choline and iron metabolism108
Molecular epidemiology of hepatitis B virus and hepatitis delta virus coinfection in-Sudan108
Oral antibiotic treatment protects mice against the development of diet-induced non-alcoholic fatty liver disease but not against diet-induced intestinal barrier dysfunction107
0.10084199905396